CAMBRIDGE, Mass., February 20, 2008 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology announced today that it has entered into a Master Research Agreement with Pfizer designed to cover current and future collaborations. The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.
Genstruct announces new collaboration with Pfizer in drug safety
MethylGene and Pharmion announce orphan drug designation for treatment of acute myelogenous leukemia
Montreal, Quebec and Boulder, Colorado. February 14, 2008 – MethylGene Inc. (TSX: MYG) and Pharmion Corporation (NASDAQ: PHRM) today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of acute myelogenous leukemia (AML) in the United States.
Apex Bioventures and Dynogen Pharmaceuticals announce definitive merger agreement
Public Company Will Have Portfolio of Late-Stage Gastrointestinal and Genitourinary Drug Candidates and Funding to Advance Compounds towards Phase 3 Pivotal Trials
HILLSBOROUGH, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Apex Bioventures Acquisition Corp. (AMEX: PEX), a publicly traded special purpose acquisition company with healthcare industry expertise, and Dynogen Pharmaceuticals, Inc., a privately owned clinical stage biopharmaceutical company focused on gastrointestinal and genitourinary disorders, announced today the signing of a definitive merger agreement.
Anthera enters into manufacturing agreements for Varespladib in preparation for pivotal Phase 3 trials
SAN MATEO, CALIFORNIA - JANUARY 31, 2008 - Anthera Pharmaceuticals, Inc. today announced it has entered into manufacturing agreements with Albemarle Corporation and Patheon Inc. The agreements provide for the large-scale clinical production of Varespladib (A-002), which is expected to be necessary in preparation for Anthera’s Phase III clinical trials and planned New Drug Application submission to the Food and Drug Administration. Varespladib is Anthera’s oral drug candidate for the treatment of cardiovascular disease.
Dynogen expands DDP225 patent estate
WALTHAM, Mass., January 16, 2008 --(BUSINESS WIRE)-- Dynogen Pharmaceuticals, Inc. today announced that the Company has acquired from Arachnova Therapeutics, Ltd. all of its worldwide patent rights and know- how related to DDP225 in an asset purchase agreement. The Arachnova patent rights, which include granted patents and pending applications related to the use of DDP225 for the treatment of functional bowel disorders, genitourinary (GU) disorders and pain, complement and enhance Dynogen’s existing extensive worldwide patent estate related to DDP225. Financial terms of the agreement were not disclosed.
Anthera announces preliminary positive results from once-daily A-002 Phase 2 cardiovascular trial
SAN MATEO, CA – January 15, 2008 – Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported preliminary results of a second Phase IIb clinical trial of A-002, for the treatment of cardiovascular disease. In this second study, administration of once-daily A-002 lowered both sPLA2 and LDL-C levels confirming the positive effects of A-002 treatment seen in the twice-daily PLASMA study (Phospholipase Levels And Serological Markers of Atherosclerosis) announced in October 2007.
Bayhill Therapeutics files registration statement for proposed initial public offering
Bayhill Therapeutics, Inc. (“Bayhill”) announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of shares of its common stock. Copies of the Bayhill registration statement on Form S-1 can be accessed over the internet through the SEC’s website at edgar.sec.gov. The number of shares to be offered and the price range for the offering have not yet been determined. All of the shares of common stock to be sold in this offering are proposed to be sold by Bayhill.
